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Abstract: Lack of coordination between the beginning of the inhalation 
and device triggering is one of the most frequent errors reported in 
connection with the use of pMDI devices. Earlier results suggested a 
significant loss in lung deposition as a consequence of late actuation. 
However, most of our knowledge on the effect of poor synchronization is 
based on earlier works on CFC devices emitting large particles with high 
initial velocities. The aim of this study was to apply numerical 
techniques to analyse the effect of late device actuation on the lung 
dose of a HFA pMDI drug emitting high fraction of extrafine particles 
used in current asthma and COPD therapy. A computational fluid and 
particle dynamics model was combined with stochastic whole lung model to 
quantify the amount of drug depositing in the extrathoracic airways and 
in the lungs. High speed camera measurements were also performed to 
characterize the emitted spray plume. Our results have shown that for the 
studied pMDI drug late actuation leads to reasonable loss in terms of 
lung dose, unless it happens in the second half of the inhalation period. 
Device actuation at the middle of the inhalation caused less than 25% 
lung dose reduction relative to the value characterizing perfect 
coordination, if the inhalation time was between 2-5 s and inhalation 
flow rate between 30-150 L/min. This dose loss is lower than the 
previously known values of CFC devices and further support the practice 
of triggering the device shortly after the beginning of the inhalation 
instead of forcing a perfect synchronization and risking mishandling and 
poor drug deposition. 
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Abstract 
Lack of coordination between the beginning of the inhalation and device triggering is one of the most 
frequent errors reported in connection with the use of pMDI devices. Earlier results suggested a 
significant loss in lung deposition as a consequence of late actuation. However, most of our 
knowledge on the effect of poor synchronization is based on earlier works on CFC devices emitting 
large particles with high initial velocities. The aim of this study was to apply numerical techniques to 
analyse the effect of late device actuation on the lung dose of a HFA pMDI drug emitting high 
fraction of extrafine particles used in current asthma and COPD therapy. A computational fluid and 
particle dynamics model was combined with stochastic whole lung model to quantify the amount of 
drug depositing in the extrathoracic airways and in the lungs. High speed camera measurements were 
also performed to characterize the emitted spray plume. Our results have shown that for the studied 
pMDI drug late actuation leads to reasonable loss in terms of lung dose, unless it happens in the 
second half of the inhalation period. Device actuation at the middle of the inhalation caused less than 
25% lung dose reduction relative to the value characterizing perfect coordination, if the inhalation 
time was between 2-5 s and inhalation flow rate between 30-150 L/min. This dose loss is lower than 
the previously known values of CFC devices and further support the practice of triggering the device 
shortly after the beginning of the inhalation instead of forcing a perfect synchronization and risking 
mishandling and poor drug deposition. 
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1. Introduction 
One of the main advantages of pressurized metered dose inhalers (pMDI) over dry powder inhalers 
(DPI) is the emission of constant active pharmaceutical ingredient (API) doses. In case of pMDIs the 
amount of drug leaving the device and its size distribution are not influenced by the breathing 
capability of the patient. However, one of the main drawbacks of pMDIs is the need for simultaneous 
device actuation and inhalation. There are several studies in the open literature reporting on the high 
fraction of patients who are not able to synchronize device triggering and the beginning of the 
inhalation (e.g. Crompton, 1982; McFadden, 1995; Molimard et al, 2003; Ivanova et al, 2016). In 
these studies the frequency of patients who had inhalation-actuation difficulties varied between 27%-
51%. Azouz et al (2013) have reported that 14% of the patients actuated the device too early, while 
35% of them actuated it too late (any actuation before the beginning of the inhalation was considered 
too early and more than 0.2 s delay after the beginning of the inhalation was considered too late). In 
their work early device actuation ranged between -0.04 s and -2.4 s, while late actuation between 0.24 s and 
1.71 s. The effect of inhalation technique when using a metered dose inhaler including the 
coordination between pMDI device actuation and inhalation on lung deposition was extensively 
studied in several earlier experimental works (e.g. Newman et al, 1980; Lawford et al, 1983; Farr et 
al, 1995; Newman et al, 1995). The main conclusion of these works was that slow inspiration 
(inspiration time > 4s) with low flow rate (around 30 L/min) and actuation at the beginning of the 
inhalation resulted in the highest lung deposition. One of the most extended studies is the work of 
Farr et al (1995) who developed a microprocessor controlled pMDI (SmartMist) and performed 
scintigraphic deposition measurements of 
99m
Tc labelled salbutamol (Ventolin) in healthy individuals. 
They compared the lung deposition fractions corresponding to early and late device actuations at 
different inhalation flow rates ranging from 30 L/min to 270 L/min. Early actuation was defined as 
actuation at a point when 10% of the total inhaled air volume is inspired, while late actuation meant 
device actuation when 55% of the total air volume is already inhaled. Late actuation caused a 
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decrease of lung deposition fraction from 14.1% to 10.6% compared to early actuation, if the 
inhalation flow rate was 30 L/min. At 270 L/min flow rate the decrease was from 8.4% to 7.6%. The 
authors concluded that delayed actuation may lead to low lung deposition especially for high 
inhalation flow rates. One decade later, Leach et al (2005) studied the effect of mis-coordination on 
the deposited lung dose of BDP (beclomethasone dipropionate, Qvar
TM
). They concluded that in case 
of a 3 s inhalation (breath-hold time: 10.5 s) a 1.5 s delay in the pMDI actuation caused less than 
20% relative lung dose loss, while a 0.5 s early actuation resulted in more than 40% loss relative to 
the case of optimal coordination. The relatively low loss corresponding to late device actuation was 
assumed to be a consequence of small particles (MMAD around 1 m), lower spray force and 
temperature and longer spray duration of HFA (hydrofluoralkane), compared to CFC 
(clorofluorocarbon) propelled pMDIs. In their recent experimental work Biswas et al (2017) has 
demonstrated that contrary to the earlier results on CFC pMDI devices, aerosol deposition emitted 
from Ventolin HFA pMDI is most optimal for actuation in the first half of inspiration at flow rates 
between 60 L/min and 90 L/min. The results of the two last publications indicate that our knowledge 
on the effect of late actuation mostly based on earlier works on CFC devices needs to be updated. 
This recognition has motivated the present numerical study, which proposes to analyse the effect of 
delayed pMDI firing on airway deposition. Among the advantages of numerical models over the 
experiments it is worth noting that a large variety of inhalation parameters and actuation delay times 
can be considered and there are no ethical barriers. In addition, computer simulations are fast, easily 
reproducible and cost effective. Different numerical techniques have been applied to quantify the 
deposition of medical aerosols emitted by both DPIs (e. g. Longest et al, 2016; Horváth et al, 2017; 
Farkas et al, 2016) and pMDIs (e.g. Yousefi et al, 2017; Longest et al, 2012; Longest et al, 2016) . 
However, to the best of the author’s knowledge, a numerical analysis of the effect of late pMDI 
device actuation is still missing in the open literature. Therefore, the objective of this study was to 
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develop, validate and apply numerical models in order to quantify the effect of delayed device 
actuation on the lung dose of a HFA pMDI drug used in current asthma and COPD therapy. 
2. Methods 
The subject of our investigation was the Foster
® 
pMDI inhalation solution (Chiesi Farmaceutici 
S.p.A.), containing a fixed-dose combination of beclomethasone dipropionate (corticosteroid) and 
formoterol fumarate (long-acting β2-agonist) used in current asthma and COPD therapy. Both 
experimental and computer modelling techniques were applied to study the airway deposition of this 
aerosol drug as a function of the degree of delay between the beginning of the inhalation and the 
actuation of the inhaler device. Transport and deposition of inhalation aerosols is a complex process 
depending on multiple factors related to the geometry of the airways, aerosol properties and 
breathing parameters. Most of the input data needed for the modelling of drug transport and 
deposition within the airways could be retrieved in the open literature. To correlate the modelling 
results with the experimental deposition measurements, particle size distribution and one of the 
simulated breathing patterns were taken from the work of de Backer et al (2010), who assessed the 
extrathoracic and lung doses of Foster
®
 pMDI drug in healthy volunteers and asthmatic and COPD 
patients by scintigraphic measurements. Based on our recent work (Horváth et al, 2017) breath-hold 
time may significantly influence the lung deposition of drugs with high amount of fine and extrafine 
particles such as Foster
®
, therefore both 5 s and 10 s breath-holds were considered in this study. In 
addition, the computations were performed for 2 s, 3 s and 5 s inhalation times and the inhalation 
flow rates were 30 L/min, 60 L/min, 90 L/min, 120 L/min and 150 L/min. These breathing data 
complemented with the main aerosol parameters are summarised in Table 1a. These aerosol 
parameters are the mass median aerodynamic diameter (MMAD), geometric standard deviation 
(GSD) of the drug size distribution, the fraction of mass depositing in the device (as a percent of the 
metered mass), the fraction of unsized particles (droplets), which are emitted, but filtered out before 
entering the impactor (expressed as a percent of the metered dose) and the fine particle fraction (FPF, 
Formatted: Indent: First line:  0 cm
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which is the mass fraction of particles with diameters smaller than 5 m expressed as a percent of 
metered dose). Table 1b contains the whole aerosol size distribution as measured by and adopted 
from De Backer et al (2010). Since aerodynamic properties of the beclomethasone (BDP) and 
formoterol (FF) components are pretty similar (Lewis et al, 2006), only the deposition of BDP was 
simulated in this study. 
 
Table 1a. Breathing and aerosol parameters used in the model calculations. Unsized particle fraction 
is the percentage of the metered dose represented by the droplets deposited in the throat of the 
impactor in the experiment of De Backer et al (2010). In the present case these are the droplets with 
diameter >10 m, though some particles even smaller than 10 m are likely to be collected on the 
inlet. FPF – fine particle fraction 
Breathing parameters Aerosol data 
Inhaled volume (L) 1.5 and 2.5 MMAD (m) 1.4 
Inhalation time (s) 2, 3 and 5 GSD 1.9 
Breath-hold time (s) 5 and 10 Unsized particle fraction (%) 53.7 
Exhalation time (s) 2, 3 and 5 FPF (%) 34.1 
Flow rate (L/min) 30, 60, 90, 120 and 150   
 
Table 1b. Size distribution of BDP adopted from De Backer et al (2010) 
Particle aerodynamic diameter (m) Dose fraction (%) 
device 9.7 
> 10 53.7 
9 - 10 1.5 
5.8 - 9 0.5 
4.7 – 5.8 0.4 
3.3 4.7 1.1 
2.1 -3.3 5 
1.1 – 2.1 13.7 
0.7 -1.1 6.9 
0.4 – 0.7 3.1 
< 0.4 4.4 
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2.1 Description of the experimental technique 
Foster
®
 has been developed based on the Modulite
®
 technology. This technology enables 
modulation of aerosol cloud formation with well-defined aerodynamic particle sizes and plume 
speeds. For this purpose the non-volatile content of a solution formula, actuator orifice geometry 
(length and diameter), metered volume and vapour pressure of the propellant are optimized. 
(Ganderton et al, 2002; Lewis et al, 2004; Lewis 2016; Gavtash et al, 2017). However, the exact 
values of the plume parameters of Foster
®
 pMDI needed for the modelling of drug deposition could 
not be found in the literature. The scope of the experimental measurements was to provide missing 
input data for the numerical model. One of the parameters measured in this work was the duration of 
the emitted aerosol bolus. This important parameter depends on several factors related to the inhaler, 
propellants and formulation. Most of the commercialized HFA pMDI products have plume durations 
between 0.1 - 0.5 s (Hochrainer et al, 2005; Gabrio et al, 1999; Johal et al, 2015). To measure the 
plume duration of Foster
®
 a high speed camera (Basler scA640-120gm, Ahrensburg, Germany) with 
a maximum time resolution of 120 frames/s, but set to 100 frames/s has been used and five 
independent measurements were performed. Another key parameter from the perspective of aerosol 
drug deposition is spray velocity, which was measured by Laser Doppler Anemometry (LDA) 
technique. The LDA equipment is an in house development of the authors (Kerekes et al, 2016). The 
laser beam was perpendicular to the plume axis with the source situated at a working distance of 40 
mm. By this technique velocities of individual particles with diameter larger than 0.5 m can be 
determined. The sampling volume was 15×80×80 m3. Axial velocity values were measured in a 
plane perpendicular to the plume axis at 20 mm distance from the mouthpiece, that is, at 45 mm from 
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the nozzle orifice, then at 40 mm and 120 mm from the mouthpiece. The near orifice value of the 
axial velocity has been estimated by extrapolating the measured values. It was assumed that the spray 
plume follows quasi-steady plume relationships described by Abramovich (1976), that is, the 
velocity is inversely proportional to the distance from the source as described by 
         
 
    
 
 
   
     (1) 
equation, where vcl and vref are centreline and reference velocities, d is the distance to the spray 
orifice, ds is the distance from the spray orifice exit to the effective plume source location, while Dso 
denotes the diameter of the orifice (0.3 mm in case of Foster
®
 inhaler, see Lewis, 2016). The scheme 
of the experimental setup is demonstrated in Figure 1. Beside spray duration and velocity, plume 
cone angle is also an important parameter influencing upper airway deposition (and indirectly also 
lung deposition). A few cone angle measurements are available in the published literature. For 
instance, Oliveira et al (2013) have measured a value of 14º for the cone angle of salbutamol HFA 
pMDI. However, the value corresponding to Foster
®
 pMDI could not be found in the open literature, 
thus it was measured in this work. In a recent work Yousefi et al (2017) have demonstrated that the 
effect of spray cone angle on particle deposition was more significant than effect of the initial spray 
velocity, thus effort has been spent to precisely determine this parameter. 
 
Figure 1. Scheme of the experimental setup for the measurement of spray velocity 
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2.2 Description of the computational model 
In our earlier works we have applied a whole respiratory system stochastic particle deposition 
model for the simulation of the deposition of drugs emitted by DPIs (dry powder inhaler; e.g. Farkas 
et al, 2016; Horváth et al, 2017, Farkas et al, 2017). The inhaled particles are tracked through a 
stochastic asymmetric lung structure by randomly selecting the sequence of airways for each 
individual particle and the application of stochastic modeling techniques (Monte Carlo method). 
The airway geometry is based on rigorous statistical analyses of the extensive morphometric data 
sets of bronchial (Raabe et al. 1980) and alveolar (Haefeli-Bleuer and Weibel 1988) airways. This 
morphology describes the inherent asymmetry and variability of the human airway system. The 
variability of airway diameters, lengths, branching and gravity angles, constrained by correlations 
among some of these parameters, is mathematically described by probability density and correlation 
functions. In agreement with the database of Raabe et al. (1980), in this model the bronchial airways 
contain both the bronchi and the bronchioli, starting from the trachea (as generation 1) and ending 
with the terminal bronchioles. The airway generation number of a terminal bronchiolus varies 
between 12 and 21. The acinar airways start with the respiratory bronchioles, which have generation 
numbers between 13 and 22, and contain the alveolar ducts, the alveoli and the alveolar sacs. The 
maximum generation number, corresponding to alveolar sacs, varies between 18 and 33. In the 
airway segment corresponding to airway generations 13–21 one part of the airways is still bronchial 
but another part is already acinar. In this study, the joint bronchial and acinar airways are termed as 
lung. 
For the simulation of particle transport through this stochastic lung structure, individual particles 
are tracked. At airway bifurcations the particles enter one of the daughter branches with probabilities 
proportional to the airflow splitting. The flow splitting between the two asymmetric daughter airways 
is assumed to be related to the peripheral air volume supported by each of them. 
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Deposition of particles in a given airway generation is computed by analytical equations 
describing the average deposition of many particles in cylindrical airways due to inertial, 
gravitational and Brownian forces (Koblinger and Hofmann 1990). In the oro-pharyngeal region 
particle deposition is computed by empirical equations derived by Cheng (2003). Due to the 
variability of the airway geometry and related flows, particle deposition may vary along different 
paths. Thus, penetration probabilities to a given airway generation, i.e., the probability of inhaled 
particles to reach that airway generation, exhibits significant fluctuations, depending on the 
individual history of each particle in upstream airways. By simulating the random paths of many 
particles, typically of the order of tens of thousands, statistical means can be calculated for total, 
regional and generational deposition, providing also information on the underlying statistical 
distributions. 
However, the upper airway sub-model of the stochastic deposition model cannot be applied for 
the inhalation phase in case of pMDI aerosols. The empirical formulas integrated in the stochastic 
deposition model were deduced for solid particles with the same entrance velocity as the velocity of 
the inhaled air, which is the case of DPI drugs. In the case of the aerosols emitted by pMDIs the 
velocity of the aerosol exceeds the velocity of the inhaled airflow and evaporation of the propellant 
solvent takes place, thus the above empirical formulas cannot be applied. Therefore, we replaced the 
upper airway part of the stochastic model by a finite volume numerical method applied in a 3D 
reconstructed mouth-throat-larynx geometry. 
Due to computing power limitations and the impossibility to digitally reconstruct many millions 
of units of the whole airway system, a fully CFPD (computational fluid and particle dynamics) based 
simulation was not a viable option. In this way our deposition model became a hybrid computational 
model with a CFPD based sub-model for the computation of upper airway deposition during 
inspiration and a stochastic analytical lung model for the modelling of lung deposition during 
inspiration, breath-hold and expiration and for the computation of extrathoracic deposition during 
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expiration. Since the stochastic model has been presented in details in our recent works, here we 
restrict to the presentation of the CFPD sub-model. 
For the prediction of drug particle trajectories during inspiration the inhaled air and the propellant 
gas were considered as continuums in which discrete droplets were injected (Euler-Lagrange 
approach). The first step of the modelling was the reconstruction of the three dimensional geometry 
of the inhaler and the upper airways of interest (oral cavity, pharynx, larynx, and beginning of the 
trachea). The digital replica of the pMDI geometry has been constructed by CAD (computer aided 
design) techniques. The three dimensional oral model was derived from the human cast of Cheng et 
al (1999). Unlike the original replica, present geometry has circular cross sections with diameters 
equal to the hydraulic diameters measured from the cast. Other minor modifications suggested by 
Kleinstreuer and Zhang (2003) were made at the level of soft palate, mouth inlet and at the glottis. 
Figure 2 demonstrates the reconstructed three dimensional geometry of the inhaler and upper airways 
with cross-sectional areas at a few anatomically relevant locations. The inhaler and airway 
geometries were unified to simulate their relative position during the inhalation of the drug and the 
unified 3D body has been spatially discretized by the application of an unstructured tetrahedral mesh. 
For this purpose the GAMBIT code (version 2.2.30) was used, which is a pre-processor of FLUENT. 
The mesh density was higher near the boundaries, where higher gradients of flow parameters are 
expected. This has been achieved by using a ‘size function technique’ included in GAMBIT. A mesh 
independency study has been performed. The mesh was consecutively refined until the converged 
solution of the monitored flow parameters remained constant. This resulted in a total number of 2.2 
million control volumes (cells). A cross section of the mesh corresponding to the mouth inlet can 
also be seen in Figure 2. 
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Figure 2. Three dimensional models of the inhaler (left) and the oral – pharyngeal - laryngeal 
airways (right). The front sidewall of the inhaler has been “removed” to make the inside components 
visible. A cross section of the numerical mesh corresponding to the mouth inlet is also demonstrated 
 
The inhaled airflow was modelled both in the inhaler and the oro-pharyngeal-laryngeal geometry. 
The density of the air was 1.23 kg/m
3
, while its viscosity was 1.79×10
-5
 kg/(m s). Based on our 
earlier work (Farkas et al, 2006) and also the work of Longest and Vinchurkar (2007) the Low 
Reynolds Number (LRN) k- turbulence model is suitable for the modelling of the airflow in this 
region of the airways. Transport equations of mass, momentum, turbulent kinetic energy and its 
dissipation rate were solved numerically by the solver of the commercially available FLUENT CFD 
code (version 6.1.22). A finite volume method has been applied to numerically solve the 
mathematical equations describing the air flow. The integral forms of the equations were discretized. 
Each discrete governing equation was linearized implicitly, then a Gauss-Seidel point implicit linear 
equation solver was used in conjunction with an algebraic multigrid (AMG) method. For the 
computation of cell face values, a second-order upwind scheme was applied. At the end of every 
iteration step, scaled residuals were computed for each conserved variable. Convergence was speed 
up by fine tuning the under-relaxation factors. About 50,000 iteration steps were needed. All the 
scaled residuals fell below 10
-4
 and remained nearly constant over the last 5,000 iteration steps. As 
boundary conditions, constant air velocity (2.68 m/s, 5.36 m/s, 8.04 m/s, 10.72 m/s and 13.4 m/s 
 trachea 
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 soft palate 
mouth 
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 tongue arc pharynx 
larynx 
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corresponding to 30 L/min, 60 L/min, 90 L/min, 120 L/min and 150 L/min inhalation flow rates) and 
3% turbulence intensity was assumed at the inhaler airflow inlet and zero gauge pressure was 
prescribed at the outlet boundary surface. 
The next step of the simulation would be to include spray injection into the stabilized airflow field. 
Due to evaporation of formulation inside the pMDI actuator the emitted spray is a mixture of 
droplets and vapour. It is difficult to assess the size distribution of the droplets at near orifice region, 
but it is known that due to the rapid evaporation of the propellant the size of droplets decreases 
drastically. Droplet evaporation rate depends on several factors being influenced, among others, by 
the concentration and vapour pressure of the cosolvent (Sheth et al, 2017). However, it was 
demonstrated that for pMDI and drug-solvent-cosolvent physico-chemical properties close to the 
present case key plume dynamics in terms of interphase phenomena takes place only in near-orifice 
region. After an axial distance of 30 mm from spray orifice (which in our case approximately 
corresponds to the exit of the mouthpiece) the droplets reach their final size and temperature 
(Gavtash et al, 2016). 
In this work the change of droplet sizes was not modelled, but the airflow field of the gas phase 
propellant was determined and polydisperse particles with constant diameters were tracked in the 
computed air and propellant flow field. Neglecting the rapid change of particle diameter within the 
first 3 cm after the nozzle orifice may induce error mainly in the estimation of particle deposition 
within the inhaler. However, for this region the experimentally measured deposition fraction (9.7%, 
De Backer et al, 2010) was adopted in this study instead of the numerical solution. Since intensive 
momentum change between evaporating and slowing down droplets and air is neglected in the first 3 
cm after the nozzle orifice, deposition outside the device (in the oral cavity) could also be indirectly 
affected. However, Longest et al (2012) have demonstrated by comparison of numerical results with 
experimental measurements that the assumption of constant particle size is not inducing significant 
errors in the estimation of upper airway deposition fractions. 
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In this study the formulation exiting the nozzle was assumed to be at the HFA 134a boiling point 
for atmospheric pressure. Conservation of mass was used to estimate the density of the slurry exiting 
the nozzle. The velocities of the propellant and particles were assumed to be the same at the orifice 
exit. Particlesize distribution was derived from the work of De Backer et al (2010). Unit density 
particles were tracked, since measured aerodynamic diameters were adopted in this study. The main 
characteristics of the distribution are depicted in Table 1a, while the whole aerosol size distribution is 
presented in Table 1b. As far as the implementation of the PSD is concerned, series of monodisperse 
particles were tracked (with diameters corresponding to the cut-offs of the impactor), then deposition 
fraction was determined as the weighted sum of the monodisperse deposition fraction values. The 
weights were identical to the values in the last column of Table 1b. 
The particles were released into the computational domain at the location of the nozzle orifice 
with initial velocity deduced from our measurements (see above). The velocity vectors of the 
particles were inside a cone with the opening angle determined by our own measurements. Particle 
trajectories were determined based on the computed airflow field by numerically integrating their 
force balance equations. It was considered that a particle deposits if its trajectory intersects the wall 
of the airways. 
The considered deposition mechanisms were inertial impaction, gravitational settling and 
turbulent dispersion. The last mechanisms was modelled by the application of a “discrete random 
walk” model included in FLUENT solver. In this model a particle interacts with a succession of 
random discrete turbulent eddies, with each eddy defined by a lifetime, length, and velocity scale. 
2.3 Model validation 
The stochastic deposition model used in this work for the modelling of particle deposition in the 
lungs at inhalation and breath-hold, and in the whole respiratory system at exhalation has been 
validated in our recent works by the help of scintigraphic deposition measurements (e.g. Farkas et al, 
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2016). Therefore, here we restrict to the validation of our CFPD model described in the previous 
paragraph. The results of the simulations of monodisperse particle upper airway deposition were 
compared to the experimental measurements of Cheng et al (1999) and to the simulation results of 
Kleinstreuer and Zhang (2003) who simulated the efficiency of particle deposition in the same upper 
airway geometry. In this case the inhaler was missing and both the air and the particles entered the 
airway geometry at the mouth inlet. The results of this comparison are presented in Figure 3. The 
Stokes number is defined here as by Cheng et al. (1999), i.e., St = pdp
2
v/9D, with v being the mean 
velocity evaluated as (Q/A), where A is the mean cross-sectional area (4.43 cm
2
) and D is the 
minimum hydraulic diameter (1.71 cm). In addition, p denotes the density of the particles, dp is 
particle diameter and  is the viscosity of air. Our simulated deposition values reasonably retrace the 
trends depicted by the data points of the above investigators. The good agreement suggests that our 
CFPD model can appropriately estimate the deposition of aerosol drugs within the upper airways. 
 
Figure 3. Comparison of deposition fractions obtained by the current CFPD model with the 
experimental data of Cheng et al (1999) and simulation results of Kleinstreuer and Zhang (2003) 
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The simulated inspiratory airflow in the pMDI device and in the upper airways for 30 L/min flow 
rate is demonstrated in Figure 4, left panel. The air enters the inhaler with a mean velocity of 2.68 
m/s and flows downwards around the canister. At the entrance to the mouth geometry the air velocity 
profile becomes skewed towards the bottom surface of the mouthpiece. However, inside the oral 
cavity the direction of the air becomes upward because the arch of the tongue. Due to the curvature 
the flow is then directed towards the throat. As a result of the decrease of the cross sectional surface 
area at the level of the larynx the flow accelerates and a so called „laryngeal jet” appears, which is 
located approximately at the centre of the tube, but closer to the inner (front) side of the geometry. 
The results related to spray injection into the stabilised airflow field are shown in Figure 4, right 
panel. The velocity field in the mid-plane demonstrates a deceleration of the propellant with the 
increase of  axial distance from the nozzle due to the momentum exchange with the air. The 
propellant and airflow characteristics will evidently influence particle deposition patterns. However, 
particle deposition simulations require a few plume parameters which were measured in this study. 
Therefore the results of these measurements will be presented first. 
 
 
 
Figure 4. Simulated inspiratory air (30 L/min flow rate, left panel) and air plus propellant (right 
panel) velocity contours coloured by velocity magnitude in the mid-sagittal symmetry plane of the 
inhaler and upper airways 
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Figure 5 shows selected high speed camera images recorded during the emission of aerosol bolus in 
quiescent air. The figure presents the plume structure at 0.05 s time intervals from the beginning of 
the emission, but the high speed camera images were detected at a time resolution of 100 s
-1
. Our 
plume visualization experiments provided a mean value of 0.194 s for the spray duration and a 
standard deviation of 0.005 s. This mean value was used in the present aerosol drug transport and 
airway deposition simulations. Besides spray duration, the visualization of plume patterns allowed us 
the measurement of spray cone angle, as well. Our measurements yielded a value of 14º for the 
whole cone opening (angle of cone generators in the same planar cone section), which means that the 
maximum injection angle (angle of particle entrance velocity vector and the axis perpendicular to the 
circular inlet in figure 2) was 7º. The measured axial plume velocity at 2 cm from the inhaler exit 
was 14±1.2 m/s. The same values at 4 cm and 12 cm were 6.9±0.6 m/s and 0.7±0.3 m/s, respectively. 
Fitting the best curve to these values based on equation 1 and extrapolating to the location of the 
orifice yielded 55 m/s initial axial velocity. 
 
 
 
Figure 5. High speed camera images of an aerosol bolus emitted by Foster
®
 pMDI taken at different 
moments of the actuation. For better visualization the colours were inverted and an image filter was 
applied. The length scale is provided in cm 
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The computed airflow fields, the measured plume parameters, the aerosol characteristics derived 
from the open literature (Tables 1a and 1b) and the selected breathing parameters were used to 
determine the extrathoracic and lung doses. The simulations were performed assuming perfect 
coordination (zero delay time) and for different non-zero actuation delay times. Based on our 
numerical simulation results at a fixed flow rate the extrathoracic deposition fractions did not change 
significantly by the variation of delay time. For instance, assuming 30 L/min inhalation flow rate and 
10 s breath-hold the extrathoracic deposition fractions were between 51.2%-54.4%, expressed as a 
percent of the metered dose. The change in upper airway deposition dose for different flow rates and 
10 s breath-hold varied between 51.2%-60.1%. This moderate extrathoracic deposition fraction 
variance as a function of flow rate and actuation delay time is due to the special size distribution of 
the studied drug. As demonstrated in Table 1a, 53.7% of the emitted aerosol particles are droplets 
with diameter larger than 10 m, while the second half of the particles are very small with an 
MMAD of only 1.4 m. Actually, the large droplets contain primarily propellant and ethanol rather 
than the residual particles, which is the case of the second mode (particles smaller than 2 microns). 
The probability of upper airway deposition of the fraction of large droplets is very high at every 
studied flow rate, while extrathoracic deposition of the aerosolized fraction (< 10 m) is constantly 
low and hardly influenced by inhalation flow rate due to the very high subfraction of extrafine (< 2 
m) particles. By the same token, impaction of large droplets in the upper airways takes place within 
milliseconds after the emission of the drug, which is a very short time compared to the inhalation 
time and even compared to the duration of the puff. Therefore, the influence of delay time to the 
extrathoracic deposition fraction is also low. Figure 6 presents the relative lung deposition (ratio of 
deposition fraction at delayed actuation to the deposition fraction at perfect coordination) values as a 
function of actuation delay time for 30 L/min inhalation flow rate (which is recommended by current 
guidelines, see GINA 2018) , 2 s (upper panel), 3 s (middle panel) and 5 s (bottom panel) inhalation 
time, 5 s and 10 s breath-hold and 2 s (upper panel), 3 s (middle panel) and 5 s (bottom panel) 
Formatted: Font color: Auto
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exhalation time. The figure demonstrates that for a firing at the middle of inhalation the relative loss 
of lung dose is less than 20%, while 50% relative loss corresponds to firing in the last quarter of the 
inhalation period. The decrease of lung deposition proved to be very high only when actuation 
happened at the very end of the inhalation period. The absolute values of the lung dose for zero 
actuation delay expressed as a percent of the metered dose were 26.6%, 29.4% and 32.6% for 2 s, 3 s 
and 5 s inhalation times and 5 s of breath-hold, and 30 %, 32% and 34.2% for 2 s, 3 s and 5 s 
inhalation times, respectively, if the breath-hold time was 10 s. The absolute values of lung doses for 
different actuation delay times can be computed by multiplying the above values with the values 
(between 0 and 1) corresponding to the actuation delay time in Figure 6. It is worth noting that all the 
results of Figure 6 refer to 30 L/min. inhalation flow rate, but only a low fraction of patients inhale 
with such a low flow rate. Indeed, our measurements on 27 healthy individuals inhaling through the 
same pMDI inhaler of Chiesi have shown that the average peak inspiratory flow rate (PIF) was 143 
L/min. In addition, our measurements on 17 COPD patients with different degrees of disease severity 
yielded an average inhalation peak flow of 99.6 L/min (Jókay et al, 2015). The results of Al-Showair 
et al (2007) are in agreement with our measurements (average PIF=110 L/min for COPD patients). 
 
Figure 6. Computed lung deposition in case of late actuation relative to the deposition at perfect 
coordination as a function of actuation delay time assuming 2 s, 3 s and 5 s inhalation time and 5 s 
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and 10 s breath-hold after the inhalation phase. Q – flow rate; tin – inhalation time; tb-h – breath-hold 
time; tout – exhalation time 
 
In a work of Ammari and Chrystyn (2013) 29 out of 34 asthmatic patients had PIF > 90 L/min. 
Moreover, there is increasing evidence that optimal flow rate through HFA pMDIs may be higher 
(e.g. Biswas et al, 2017; Cheng et al, 2001). Haidl et al (2016) have defined a maximum flow rate of 
120 L/min as a “useful upper limit” for HFA pMDIs. Therefore, present investigations were 
extended also to higher inhalation flow rates. Deposition distribution of Foster
®
 has been computed 
for 60 L/min, 90 L/min, 120 L/min and 150 L/min inhalation flow rates and different actuation delay 
time values. In these simulations the inhalation time was 2 s, the breath-hold time was 10 s and the 
exhalation time was 2 s. Figure 7 demonstrates the evolution of lung doses as a function of the delay 
time of the actuation compared to the beginning of the inhalation for the five selected flow rates. The 
lung dose on the vertical axis is expressed as a percent of lung dose at perfect coordination. 
 
Figure 7. Effect of late actuation on the lung dose for different inhalation flow rates. The lung dose 
on the vertical axis is expressed as a percent of lung dose at perfect coordination (zero delay time). 
tin – inhalation time; tb-h – breath-hold time; tex –exhalation time 
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measurements revealed that healthy individuals inhaled 3.7 L of air (range: 2.6-5.1) through Foster
®
 
pMDI. Patients may inhale less air volume than healthy individuals, thus considering the highest 
flow rate may have only academic importance. However, the role of Figure 7 was to capture the 
main tendencies by increasing the flow rate. The tendencies are so clear that avoiding the highest 
flow rate (which may be not realistic (due to the above reason) would not influence the outcome of 
the figure. The figure demonstrates that the tendencies observed for 30 L/min hold also for higher 
flow rates and actuation of the pMDI as late as the middle of the inhalation period causes a relative 
lung dose loss of less than 20%. Nevertheless, this loss could lead to significantly lower lung doses 
at high flow rates if the absolute value of lung dose was sensitive to the flow rate. However, our 
simulation results have shown that for 0 s actuation delay the value of lung dose as a percent of 
metered dose decreased from 30% to only 26.4%, while the flow rate increased from 30 L/min to 
150 L/min. The physical reason for the low change in the lung doses is due to the high fraction of the 
emitted extrafine particles. Deposition of these particles is mostly due to gravitational settling and 
possibly thermal diffusion, while impaction becomes less important. The last mechanism could be 
important mainly for particles smaller than 100 nm. Most of the current drugs do not have a 
significant amount of drug in this size range. However, deposition by gravitational settling depends 
on the residence time rather than on flow rate. This fact reflects also in the presently computed only 
slightly changing lung doses. Based on these results lung deposition of Foster
®
 remains higher than 
20% even at high flow rates and actuation at the middle of inhalation phase. Since patients with such 
a poor inhalation-actuation and inhaling with undesirable high flow rate receive more than two thirds 
of the lung dose characteristic of the ideal case of perfect coordination and low flow rate, for the 
studied drug the probability of the worsening of the clinical outcome is low. Since drug receptors are 
nonuniformly distributed within the lung, from the perspective of therapeutic effect it would be 
interesting to further differentiate lung deposition. Technically this would be possible, since the 
stochastic deposition model is able to provide the deposited amount even at airway generation level. 
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However, this was not the scope of the current work. More importantly, based on the present results 
for individuals with decreased lung capacity (severe COPD patients, old patients) and for whom the 
use of DPIs is not an appropriate choice, and who are not able to perfectly synchronize pMDI 
actuation with their breathing but who are able to actuate the pMDI in the first half of the inhalation 
phase, the use of Foster pMDI can also be a viable option. It is also worth noting that even the 
inhalation through breath-actuated devices leads to some delay in drug emission. For instance, the 
release of the drug from the Autohaler
®
 breath-actuated device begins at a mean delay time of 0.18 s 
after the beginning of the inhalation (Leach et al, 2005). Present results also suggest that the effect of 
delayed actuation on the dose deposition within the lungs of the patients could be more pronounced 
for drugs with higher fractions of large emitted particles. However, the demonstration of this 
hypothesis falls beyond of the scope of the present work. Since most of our perceptions on the effect 
of poor coordination are based on earlier works on CFC pMDIs with higher spray velocity and 
emitting higher fractions of large particles, studies on currently marketed HFA pMDIs emitting drugs 
with different particle size distributions are highly needed. It is worth noting that the results in 
figures 6 and 7 refer to constant inhalation flow rates. In reality the inhalation flow curve can have 
various shapes. The left panel of Figure 8 demonstrates two realistic flow profiles selected from our 
database of curves emerging while patients inhale through the Foster
®
 device. The two curves were 
selected based on inhalation time (about 5 s) and the mean flow rate (about 60 L/min) to compare 
them with the case of 60 L/min constant flow. One of the curves (type A) shows a case when the 
patient inhales forcefully at the beginning of the inhalation then the flow rate decreases, while the 
second curve (type B in the figure) corresponds to a patient who was able to breath with a relatively 
constant force. Most of the inhalation profiles fall between these two cases. Since it is not expected 
that profile B will lead to results significantly different from the case of constant flow rate, only the 
deposition corresponding to profile A was computed. Although the upgrade of our hybrid numerical 
model to unsteady cases is in progress, at this moment only steady flows can be simulated. Therefore, 
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the type A flow profile was approximated with a stair-shaped profile (see the left panel of Figure 8). 
The corresponding inhalation flow rates were 140 L/min between 0 s and 1 s, 110 L/min between 1 s 
and 2 s, 80 L/min between 2 s and 2.5 s, 30 L/min between 2.5 s and 3 s, 10 L/min between 3 s and 4 
s and 5 L/min between 4 s and 5 s. 
 
Figure 8. Realistic and idealized inhalation flow profiles (left panel) and relative lung deposition as a 
function of actuation time for realistic unsteady (typeA) and constant flows. Q = 60 L/min; T in = 5 s 
 
Figure 8 demonstrates that using a constant flow profile we may slightly overestimate the decrease of 
lung dose due to late actuation if the delay time is relatively small (below 1.5 s) and significantly 
underestimate it for larger delay time values. To understand the causes of the differences between the 
results corresponding to steady and time dependent cases it should be emphasized that if the flow 
rate is constant, then the decrease of lung dose is caused by the lower particle residence times inside 
the lungs and because particles entering the airways cannot penetrate into the deeper airways (the 
lungs are partly full with the air entering before the inhalation of drug particles). On the other hand, 
when time dependent flow rate is considered two competing effects due to late actuation can be 
captured. At late actuation the inhalation flow rate is decreased which causes lower upper airway 
deposition fraction and concomitantly higher lung deposition. At the same time, due to late 
inhalation the drug cannot penetrate deeply in the lungs (which are already almost full) and also 
particles have less time to deposit by settling before exhalation. Therefore, this second effect causes 
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lower lung deposition. Based on our computations the first effect is more powerful mainly in the first 
part of the inhalation time period, while the second predominates toward the end of inhalation. 
Therefore, the unsteady lung dose decay is lower at the beginning, then drastically enhances. More 
importantly, based on the results in Figure 8 the main conclusion of figures 6 and 7, that is, the 
decrease of lung dose is not very significant until the middle of the inhalation time remains valid also 
when considering unsteady flow profiles. 
Last but not least, it is worth noting that besides late actuation, early actuation is also a serious 
problem, although it is less frequent than late actuation (Azouz et al, 2013). The reason this study 
focused only on late actuation is technical. The stochastic whole airway deposition model is based on 
analytical deposition formulas which are functions of air velocity, thus currently it cannot simulate 
the deposition without airflow. Its development in this direction will be the subject of a future work. 
Conclusions 
Present work has demonstrated that numerical models can be powerful tools in the quantification 
of airway deposition distribution of the inhaled aerosol drugs. Current results obtained by combining 
CFPD techniques and analytical models suggest that, at least in the case of pMDIs emitting high 
fraction of extrafine particles with moderate velocity, late actuation (up to the middle of the 
inhalation) does not cause a drastic reduction of lung dose, which was earlier observed for CFC 
devices and larger particles. Lung deposition of Foster
®
 remained reasonably high even assuming 
poor coordination, unless the actuation of the device happened at the second half of the inhalation. 
The decrease of lung deposition fraction due to late device actuation was fairly low at all the inhaled 
volumes, inhalation times and breath-hold times considered in this study, assuming that actuation is 
in the first half of the inhalation period. It is well known that many patients are unable to achieve a 
good synchronization. In such cases, it may be plausible to advice the patients to trigger the device as 
soon as possible after the beginning of the inhalation, rather than forcing them to perform two 
simultaneous activities with the risk of mishandling and poor drug deposition. Although it was not 
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the aim of this work to analyse the exact effect of premature device triggering, it is known that late 
actuation causes less deposition loss then premature activation (Leach et al, 2005). By advising the 
patients to actuate the device shortly after the beginning of the inhalation the chances of premature 
actuation will also be reduced. Present work is the first step of a more extended study of the effect of 
delayed pMDI actuation. Study of the effect of late actuation for drugs emitting larger particles with 
higher flow rate dependency of drug deposition is needed in the future. 
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